SCHEMBL311201

SCHEMBL311201

O=c1c(-c2ccc(O)cc2)coc2ccccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.71
MAOA P21397 8/20 0.71
ALDH1A1 P00352 6/20 0.71
SMN1; SMN2 Q16637 6/20 0.71
HPGD P15428 5/20 0.71
KDM4E B2RXH2 4/20 0.71
NPC1 O15118 4/20 0.71
RAB9A P51151 4/20 0.71
HSD17B10 Q99714 4/20 0.71
ALDH2 P05091 4/20 0.71
HDAC6 Q9UBN7 4/20 0.71
CYP3A4 P08684 4/20 0.71
TP53 P04637 3/20 0.71
MAPT P10636 3/20 0.71
CYP2C9 P11712 3/20 0.71
CYP2C19 P33261 3/20 0.71
CYP2D6 P10635 2/20 0.71
AKR1B10 O60218 2/20 0.71
LMNA P02545 2/20 0.71
TTR P02766 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoflavone SCHEMBL28075346 0.92 ALDH1A1 (0.70) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Daidzein SCHEMBL2025991 0.90 KDM4E (0.86) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL3066716 0.88 ALOX12 (0.80) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Daidzein SCHEMBL28743634 0.87 KDM4E (0.76) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL8028 0.86 ALDH1A1 (0.66) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL6542422 0.86 ALDH1A1 (0.66) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL6290885 0.86 ALDH1A1 (0.66) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL31264756 0.86 ALDH1A1 (0.66) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL27523008 0.85 ALDH1A1 (0.65) MAOBMAOAALDH1A1SMN1; SMN2HPGD
Isoflavone SCHEMBL4941824 0.84 ALOX15 (0.76) MAOBMAOAALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60048924-A None JP disclosed
US-20230330059-A1 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME NEUROBIONET, INC. (KR) 2023-10-19 US disclosed
CN-106061476-B Use of isoflavones for treating retroviral infections 港大科桥有限公司 2021-06-08 CN disclosed
EP-3082799-B1 USE OF ISOFLAVONES FOR THE TREATMENT OF RETROVIRAL INFECTION VERSITECH LTD (CN) 2021-04-28 EP disclosed
EP-3082799-A1 USE OF ISOFLAVONES FOR THE TREATMENT OF RETROVIRAL INFECTION Versitech Limited (CN) 2016-10-26 EP disclosed
WO-2015090201-A1 USE OF ISOFLAVONES FOR THE TREATMENT OF RETROVIRAL INFECTION VERSITECH LIMITED (CN) 2015-06-25 WO disclosed
US-8742141-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2014-06-03 US disclosed
US-8742141-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2014-06-03 US disclosed
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-11-07 US disclosed
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-11-07 US disclosed
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-08-28 US disclosed
US-7368434-B2 Compounds useful for the inhibition of ALDH THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 2008-05-06 US disclosed
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-02-07 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed
EP-1542675-A1 COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH The Endowment For Research In Human Biology, Inc. (US) 2005-06-22 EP disclosed
US-20040068003-A1 Compounds useful for the inhibition of ALDH THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC, 2004-04-08 US disclosed
WO-2004002470-A1 COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 2004-01-08 WO disclosed
JP-S6048924-A REMEDY FOR OSTEOPOROSIS TAKEDA CHEM IND LTD 1985-03-16 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 MAOB 385/4885MAOA 251/4885ALDH1A1 1211/4885
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 MAOB 2694/4885MAOA 2714/4885ALDH1A1 1204/4885
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 MAOB 47/4885MAOA 62/4885ALDH1A1 1/4885
US-20230330059-A1 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME APP, BACE1, MAPT MAOB 1168/4885MAOA 492/4885ALDH1A1 1317/4885
US-20040068003-A1 Compounds useful for the inhibition of ALDH ALDH2, ALDH1A1, ALDH3A1 MAOB 399/4885MAOA 484/4885ALDH1A1 2/4885
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION ALDH1A1, ADH1A, ALDH3A1 MAOB 45/4885MAOA 62/4885ALDH1A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.